Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of zolbetuximab alone and in combination regimens in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma
jRCT2080225325Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of zolbetuximab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (5 arms), sponsored by Astellas Pharma. Started Aug 2020; status: completed.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080225325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225325.